5. AM Klutz, ZG Gao, J Lloyd, A Shainberg, KA Jacobson. Enhanced A_3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates. J Nanobiotechnol. 2008 Oct 23;6:12.

Patent Status

- U.S. Provisional Application No. 60/947,121 filed 20 Jun 2007 (HHS Reference No. E–219–2007/0–US–01).
- U.S. Provisional Application No. 61/045,498 filed 16 Apr 2008 (HHS Reference No. E–219–2007/1–US–01).
- International Application No. PCT/US08/067683 filed 20 Jun 2008, which published as WO2009/006046 on 08 Jan 2009 (HHS Reference No. E–219–2007/2–PCT–01).
- U.S. Patent Application No.12/143,451 filed 20 Jun 2008, which published as U.S. 20090012035 on 08 Jan 2009 (HHS Reference No. E–219–2007/2–US–02).

Licensing Status: Available for licensing.

Licensing Contact: Cristina Thalhammer-Reyero, PhD, MBA; 301–435–4507; *thalhamc@mail.nih.gov*.

Collaborative Research Opportunity: The Laboratory of Bioorganic Chemistry of the National Institute of Diabetes & Digestive & Kidney Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize dendrimer conjugates of suitably functionalized small molecule ligands of adenosine receptors and P2Y nucleotide receptors. Please contact Dr. Kenneth A. Jacobson at 301–496–9024, or e-mail *kajacobs@helix.nih.gov*, for more information.

Dated: March 19, 2009.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E9–6935 Filed 3–27–09; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

SUMMARY: The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of Federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

M2e Peptide Vaccine Against Influenza Virus

Description of Technology: The invention offered here is a vaccine candidate that can potentially confer protection against many types of influenza. Current vaccines against influenza virus are comprised of inactivated virus or purified influenza virus proteins and are targeted primarily to induce neutralizing antibodies against the viral hemagglutinin (HA) protein. The virus can mutate or shift antigenic types of HA rapidly rendering the vaccines ineffective and thus the vaccine has to be evaluated yearly to predict next year's circulating strains for vaccine preparation. Unlike HA, the small M2 protein is highly conserved among different strains of influenza virus and thus vaccines based on the M2 protein have the potential to be effective against different strains of influenza. The current invention relates to peptide vaccines composed of the extracellular domain of the M2 protein (M2e) conjugated to a carrier protein. In animals studies a mutant diphtheria toxin-M2e—conjugate induced high antibody levels to both vaccine components in mice.

Applications:

- Preventative and therapeutic for influenza virus.
- Vaccine against seasonal and pandemic influenza virus strains.

Advantages: Novel vaccine candidate with potential heterosubtypic protection.

Development Status: In vitro and *in vivo* data can be provided upon request.

Market: Influenza virus vaccines.

Inventors: Mark A. Miller (FIC), Rachel Schneerson (NICHD), Joanna Kubler-Kielb (NICHD), John B. Robbins (NICHD), Zuzanna Biesova (NICHD), and Jerry Keith (NICHD).

Patent Status: U.S. Provisional Application No. 61/089,384 filed 15 Aug 2008 (HHS Reference No. E–304–2008/0–US–01).

Licensing Status: Available for licensing.

Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; *changke@mail.nih.gov*.

Therapeutic HIV Vaccine and Associated Protocols

Description of Technology: This technology describes a therapeutic HIV DNA vaccine to be administered to individuals who have previously experienced or are undergoing antiretroviral therapy (ART). The therapeutic DNA vaccine can also be administered in combination with a vector encoding an IL–15 and/or IL–15 receptor alpha (IL–15Ra) polypeptide. In primate studies, the technology was found to be particularly effective when the vaccine composition was administered by electroporation and expressed six (6) HIV antigens (including two (2) gag polypeptides and two (2) envelope polypeptides) and IL–15 and IL–15Ra. The antigens are typically modified with a destabilizing sequence, a secretory polypeptide and/or a degradation signal. Successive administration up to as many as nine resulted in continual boost of the immune response against the encoded antigen. A potent immunotherapeutic vaccine as described here could be an important technology for the fight against HIV/AIDS.

Applications: Therapeutic HIV DNA vaccines.

Development Status: Primate data available.

Inventor: Barbara Felber *et al.* (NCI).

Patent Status:

PCT Application No. PCT/US2008/51004 filed 14 Jan 2008, which published as WO 2008/089144 on 24 Jul 2008 (HHS Reference No. E–103–2007/0–PCT–02); claiming priority to 12 Jan 2007.

PCT Application No. PCT/US2007/000774 filed 12 Jan 2007, which published as WO 2007/084342 on 26 Jul 2007 (HHS Reference No. E–254–2005/2–PCT–01); claiming priority to 13 Jan 2006. National Stage filed in AU, BR, CA, CN, EP, IL, IN, JP, MX, NZ, and US.

PCT Application No. PCT/US2001/45624 filed 01 Nov 2001, which published as WO 2002/36806 on 10 May 2002 (HHS Reference No. E–308–2000/0–PCT–02); claiming priority to 01 Nov 2000. National Stage filed in AU, CA, EP, JP, and US.

U.S. Patent Application No. 11/571,879 filed 09 Jan 2007 (HHS Reference No. E–249–2004/1–US–02).

Licensing Status: Available for licensing.

Licensing Contact: Kevin W. Chang, Ph.D.; 301–435–5018; *changke@mail.nih.gov*.

Collaborative Research Opportunity: The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize HIV DNA vaccines. Please contact John D. Hewes, Ph.D. at 301–435–3121 or *hewesj@mail.nih.gov* for more information.

Dated: March 19, 2009.

Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E9–6936 Filed 3–27–09; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Environmental Health Sciences Special Emphasis Panel; NIH Loan Repayment Program Regarding Clinical & Pediatric Researchers.

Date: April 29, 2009.

Time: 2 p.m. to 5 p.m.

Agenda: To review and evaluate grant applications.

Place: NIEHS/Keystone Bldg., Keystone Building, 530 Davis Drive, Research Triangle Park, NC 27709.

Contact Person: RoseAnne M McGee, Associate Scientific Review Administrator, Scientific Review Branch, Division of Extramural Research and Training, Nat. Institute of Environmental Health Sciences, P.O. Box 12233, MD EC–30, Research Triangle Park, NC 27709. (919) 541–0752. *mcgee1@niehs.nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.115, Biometry and Risk Estimation—Health Risks from Environmental Exposures; 93.142, NIEHS Hazardous Waste Worker Health and Safety Training; 93.143, NIEHS Superfund Hazardous Substances—Basic Research and Education; 93.894, Resources and Manpower Development in the Environmental Health Sciences; 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing, National Institutes of Health, HHS)

Dated: March 23, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9–6930 Filed 3–27–09; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Center for Substance Abuse Prevention; Notice of Meeting

Pursuant to Public Law 92–463, notice is hereby given that the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Substance Abuse Prevention (CSAP) National Advisory Council will meet on April 30, 2009 from 1 p.m. to 3 p.m. via teleconference.

The meeting will include discussion and evaluation of grant applications reviewed by Initial Review Groups. Therefore, the meeting will be closed to the public as determined by the Acting Administrator, SAMHSA, in accordance with Title 5 U.S.C. 552b(c)(6) and 5 U.S.C. App. 2, Section 10(d).

Substantive program information, a summary of the meeting, and a roster of Council members may be obtained either by accessing the SAMHSA Committee's Web site at *https://nac.samhsa.gov/CSAPcouncil/index.aspx* as soon as possible after the meeting, or by contacting CSAP National Advisory Council's Designated Federal Official, Ms. Tia Haynes (see contact information below).

Committee Name: Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Prevention National Advisory Council.

Date/Time/Type: April 30, 2009, 1 p.m. to 3 p.m.: CLOSED.

Place: 1 Choke Cherry Road, Conference Room 4–1058, Rockville, Maryland 20857.

Contact: Tia Haynes, Designated Federal Official, SAMHSA/CSAP National Advisory Council, 1 Choke Cherry Road, Room 4–1066, Rockville, MD 20857, Telephone: (240) 276–2436; FAX: (240) 276–2430, E-mail: *tia.haynes@samhsa.hhs.gov*.

Toian Vaughn,

Committee Management Officer, Substance Abuse and Mental Health, Services Administration.

[FR Doc. E9–6960 Filed 3–27–09; 8:45 am]

BILLING CODE 4162–20–P

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

[Docket No. USCG–2009–0192]

Prince William Sound Regional Citizens' Advisory Council (PWSRCAC) Charter Renewal

AGENCY: Coast Guard, DHS.

ACTION: Notice of recertification.

SUMMARY: The purpose of this notice is to inform the public that the Coast Guard has recertified the Prince William Sound Regional Citizens' Advisory Council (PWSRCAC) as an alternative voluntary advisory group for Prince William Sound, Alaska. This certification allows the PWSRCAC to monitor the activities of terminal facilities and crude oil tankers under the Prince William Sound Program established by statute.

DATES: This recertification is effective for the period from February 28, 2009, through February 28, 2010.

FOR FURTHER INFORMATION CONTACT: LCDR Gary Koehler, Seventeenth Coast Guard District, by telephone at (907) 463–2809, or by mail at 709 W. Ninth Street, Juneau, Alaska 99801.

SUPPLEMENTARY INFORMATION:

Background and Purpose

As part of the Oil Pollution Act of 1990 (OPA 90), Congress passed the Oil Terminal and Oil Tanker Environmental Oversight and Monitoring Act of 1990 (the Act), 33 U.S.C. 2732, to foster a long-term partnership among industry, government, and local communities in overseeing compliance with environmental concerns in the operation of crude oil terminals and oil tankers.

On October 18, 1991, the President delegated his authority under 33 U.S.C 2732(o) to the Secretary of Transportation in Executive Order 12777, section 8(g) (see 56 FR 54757; Oct. 22, 1991), for purposes of certifying advisory councils, or groups, subject to the Act. On March 3, 1992, the Secretary redelegated that authority to the Commandant of the Coast Guard (see 57 FR 8582; Mar. 11, 1992). The